Meiji Seika Is Latest To Kick Off Ustekinumab Phase III
Sees Positive Phase I Results For Stelara Biosimilar With Dong-A Socio Holdings
Meiji Seika and Dong-A Socio Holdings have become the latest developers to announce the start of Phase III trials for an ustekinumab biosimilar rival to Stelara.
You may also be interested in...
Japan’s Meiji Seika Pharma and Korea’s Dong-A have struck an exclusive licensing deal with Intas for global rights to the pair’s DMB-3115 proposed ustekinumab biosimilar to Stelara.
Samsung Bioepis has become the latest firm to move an ustekinumab biosimilar into Phase III trials, with the firm’s SB17 proposed Stelara rival kicking off a study in plaque psoriasis patients.
Bio-Thera has joined the ranks of biosimilars developers that have rivals to Stelara in Phase III trials, after kicking off a study for its BAT2206 proposed version of ustekinumab.